183
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Adherence to Treatment Recommendations for Chronic Obstructive Pulmonary Disease - Results from the Swedish National Airway Register

, , , &
Pages 909-918 | Published online: 06 Apr 2021

References

  • Läkemedelsverket Medical Products Agency (Sweden). Läkemedelverkets expert panel. [Farmakologisk behandling av kroniskt obstruktiv lungsjukdom (KOL) - behandlingsrekommendationer]; 2015. Available from: https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/behandlingsrekommendationer/sok-behandlingsrekommendationer/lakemedel-vid-kroniskt-obstruktiv-lungsjukdom-kol--behandlingsrekommendation. Accessed March 29, 2021
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2011. Available from: https://goldcopd.org/gold-reports/. Accessed March 29, 2021
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2017. Available from: https://goldcopd.org/gold-reports/. Accessed March 29, 2021
  • Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. doi:10.1186/s12931-019-1193-9
  • Sulku J, Janson C, Melhus H, et al. A cross-sectional study assessing appropriateness of inhaled corticosteroid treatment in primary and secondary care patients with COPD in Sweden. Int J Chron Obstruct Pulmon Dis. 2019;14:2451–2460. doi:10.2147/COPD.S218747
  • Stridsman C, Konradsen J, Vanfleteren L, et al. The Swedish National Airway Register (SNAR) – development, design and utility to date. Eur Clin Respir J. 2020;7(1):1833412. doi:10.1080/20018525.2020.1833412.
  • Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340(25):1948–1953. doi:10.1056/NEJM199906243402503
  • Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819–1823. doi:10.1016/S0140-6736(98)10019-3
  • Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–919. doi:10.1183/09031936.03.00027003
  • Chalmers JD, Tebboth A, Gayle A, Ternouth A, Ramscar N. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. NPJ Prim Care Respir Med. 2017;27(1):43. doi:10.1038/s41533-017-0040-z
  • Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–223. doi:10.1016/S2213-2600(13)70040-7
  • Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81. doi:10.1183/09031936.03.00031402
  • Kaplan AG. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:2535–2548. doi:10.2147/COPD.S93321
  • Sundh J, Aberg J, Hasselgren M, et al. Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014. Eur Clin Respir J. 2017;4(1):1409060. doi:10.1080/20018525.2017.1409060
  • Thomas M, Radwan A, Stonham C, Marshall S. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD. 2014;11(3):300–309.
  • Maniscalco M, Martucci M, Fuschillo S, de Felice A, D’Anna SE, Cazzola M. A case scenario study on adherence to COPD GOLD recommendations by general practitioners in a rural area of southern Italy: the “progetto PADRE”. Respir Med. 2020;170:105985. doi:10.1016/j.rmed.2020.105985
  • Marmy JL, Diedrich JP, Cadus C, et al. Adherence to GOLD recommendations among Swiss pulmonologists and general practitioners. COPD. 2020;1–10.
  • Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217. doi:10.2147/COPD.S91694
  • Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. doi:10.1016/S2213-2600(14)70065-7
  • Singh D, D’Urzo AD, Donohue JF, et al. An evaluation of single and dual long-acting bronchodilator therapy as effective interventions in maintenance therapy-naive patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:2835–2848. doi:10.2147/COPD.S217710
  • Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319. doi:10.1016/j.rmed.2015.08.002
  • Houben-Wilke S, Janssen DJA, Franssen FME, Vanfleteren L, Wouters EFM, Spruit MA. Contribution of individual COPD assessment test (CAT) items to CAT total score and effects of pulmonary rehabilitation on CAT scores. Health Qual Life Outcomes. 2018;16(1):205. doi:10.1186/s12955-018-1034-4
  • Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385
  • Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-8
  • Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
  • Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-7
  • Harlander M, Barrecheguren M, Turel M, Miravitlles M. Should patients switched from D to B in the GOLD 2017 classification be discontinued from Inhaled Corticosteroids? COPD. 2017;14(5):465–468. doi:10.1080/15412555.2017.1342233
  • Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population. Int J Chron Obstruct Pulmon Dis. 2019;14:853–861. doi:10.2147/COPD.S189585